TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05057455

Intervention type: PROCEDURE
Intervention: cytokine hemadsorption
Description: the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
Study: NCT01286493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccines on day 0 and 3
Description: All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,30,90,180,360
Study: NCT04326634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: controlled exercises
Description: controlled exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: controlled exercises
Description: controlled exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non controlled exercises group
Description: non controlled exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non controlled exercises group
Description: non controlled exercises
Study: NCT01261559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chrysalis breast displacement device
Description: Chrysalis is a cloth device secured with velcro and buckles around the upper abdomen and chest following manual cephalad breast displacement.
Study: NCT01054079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet hydrochloride
Description: Given PO
Study: NCT04569838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride injection
Description: Bendamustine is a bifunctional alkylating agent. It cross-links DNA single strand and double strand by alkylation,then destroys the function and synthesis of DNA, and makes the DNA and protein, protein and protein cross-linking, has potential to treat various tumors
Study: NCT04138160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5:2 Intermittent energy restriction
Description: Substantial (70%) energy restriction for 2 non-consecutive days/week interspersed with normal energy intake (isoenergetic) on the remaining 5 days of the week.

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous energy restriction
Description: 20% energy restriction each day relative to the energy requirement.
Study: NCT00775489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal steroid Beclomethasone
Description: Beclomethasone nasal steroids to be given to a very well controlled glaucoma patients to find if this normal dose will lead to increase in intraocular pressure up to 20% where the study will be stopped at this point.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: control group will receive normal saline inhaler
Study: NCT01536301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care morphine hydrochloride
Description: Post-operative analgesia including morphine (patient controlled analgesia).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Post-operative analgesia including oxycodone (patient controlled analgesia).
Study: NCT00595062

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra Operative Radiation Therapy (IORT)
Description: Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)
Study: NCT02417805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention: Remote Ischemic Preconditioning
Description: Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention: Remote Ischemic Preconditioning
Description: Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention: Remote Ischemic Preconditioning
Description: Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention: Remote Ischemic Preconditioning
Description: Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
Study: NCT02549651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
Study: NCT00385684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone/APAP w placebo PRN
Description: Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.
Study: NCT03168867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The 3Ms Intervention
Description: The 3 Ms is a brief e-health intervention delivered via an internet-based software application (CIAS) that incorporates principles of Motivational Interviewing. The goal of the 3 Ms intervention is to increase caregiver motivation to supervise children's daily diabetes care. The intervention consists of 3 brief sessions that are delivered at routine diabetes clinic appointments.
Study: NCT02776618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: running subcuticular closure of excisional defect
Description: Excisional defects will be repaired with deep polyglactin 910 sutures, followed by each half of the wound given randomly assigned subcuticular superficial closure as described in the treatment arms.
Study: NCT00385684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocodone/APAP
Description: Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
Study: NCT00385684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo with hydrocodone/APAP PRN
Description: Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.
Study: NCT03065582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Product A
Description: topical application sunscreen containing topical antioxidants and sunscreen filters
Study: NCT01883453

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucose oxidase+5%glucose
Description: A hydrogen peroxide producing enzyme

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline+5%glucose
Description: Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
Study: NCT03065582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Product B
Description: topical application of product A without topical antioxidants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical Product C
Description: Topical application of antioxidants only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No product applied
Study: NCT03685565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermabond and steristrips
Description: Laceration repaired with Dermabond with underlying steristrips

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond
Description: Laceration repaired with Dermabond
Study: NCT01002638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEGADERM®
Description: It consists of the occlusive application of two Tegaderm®, a plastic dressing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: It consists of pulp reconstruction by a flap (for example palmar V-Y advancement flaps of Atazoy).
Study: NCT01772537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoflurane
Study: NCT04675580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toy Talk
Description: Language modeling strategy encouraging caregivers to (1) talk about the toys the child is playing with, including the states, actions, and properties of the toys and (2) give the object its name using a lexical noun phrase.
Study: NCT00614770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard of care colonoscopy
Description: Standard White Light Colonoscopy~one exam per patient

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: Narrow Band Imaging Colonoscopy~one exam per patient

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard of care colonoscopy
Description: High Definition White Light Colonoscopy~one exam per patient
Study: NCT03713905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-010
Description: Recombinant Human Anti-PD-1 Monoclonal Antibody
Study: NCT02642744

Intervention type: OTHER
Group type: OTHER
Intervention: Nursing care model
Description: Subjects will be randomized into either the attending nursing model of care vs the standard nursing model
Study: NCT01708096

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modifast
Description: 2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Normal diet
Description: normal diet 2 weeks before gastric by-pass
Study: NCT00536913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 40/2.25ug + spacer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 40/2.25 ug
Study: NCT03725228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Magnesium Sulfate 15mg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 1,5mg/kg/h
Study: NCT02323607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study: NCT03616106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infographic intervention
Description: All study participants will receive health education using infographics during their regularly scheduled clinic appointments.
Study: NCT02193880

Intervention type: DEVICE
Group type: OTHER
Intervention: Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
Description: Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
Study: NCT03317548

Intervention type: DIAGNOSTIC_TEST
Intervention: progesterone
Description: according progesterone level to decide fresh or frozen embryo transfer
Study: NCT02323607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02299102

Intervention type: DEVICE
Group type: OTHER
Intervention: Jamshidi Manual Standard Device
Description: Jamshidi Manual Standard Device

Intervention type: DEVICE
Group type: OTHER
Intervention: OnControl Powered Ported Device
Description: OnControl Powered Ported Device
Study: NCT03222882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: personal embryo transfer
Description: According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
Study: NCT01945918

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management support education
Description: Same as Arm Description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Connection to Health Interactive Behavior Change Technology
Description: Same as Arm Description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connection to Health Interactive Behavior Change Technology
Description: Same as Arm Description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connection to Health plus Coaching (CTH+C)
Description: Same as Arm Description
Study: NCT00701662

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vivaglobin
Study: NCT02082938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bracing
Description: Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
Study: NCT04936984

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS (Patheon)
Description: single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
Study: NCT01107444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2181308
Description: Administered intravenously
Study: NCT04103866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvederm Voluma
Description: Juvederm will be used in various parts of the foot to increase collagen volume and decrease high pressures of stress typically seen as people age. It will serve to promote the following: foot cushioning due to tissue atrophy, increase comfort when walking, decrease gait peak pressures which will decrease stress on bones and soft tissue and heal calluses, skin lesions, etc. It will also decrease the patient need for balancing and offloading by the use of an in-shoe orthotic device that requires a closed shoe system. Many people complain of pain walking barefoot, in high heels and sandals where orthotics are not effective.
Study: NCT03761329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mini-Bier's block with lidocaine 0.5% 25ml
Description: An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the forearm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (25ml lidocaine 0.5%). The tourniquet remains inflated for 10 minutes to reduce systemic toxicity reactions postoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bier's block with lidocaine 0.5% 40ml
Description: An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the upper arm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (40ml Lidocaine 0.5%). The tourniquet remains inflated for 25 minutes to reduce systemic toxicity reactions postoperatively.
Study: NCT01260454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qutenza (8% capsaicin)
Description: We will place a Qutenza (8% capsaicin) patch onto an area of normal, anesthetized skin for 60 minutes. Within 28 days, subjects will place a new treprostinil infusion site into the area of Qutenza pre-treated skin.
Study: NCT00946309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Sulforaphane Extract (Broccoli Sprout Extract)
Description: 100 umol sulforaphane, every other day for 5 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose NF (placebo)
Description: 250 mg every other day for 6 weeks
Study: NCT03502850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASK120067
Description: patients take ASK120067 orally once per day at 40,80,160,240,320,480mg
Study: NCT03417050

Intervention type: OTHER
Intervention: No intervention will take place for this retrospective and observational study.
Description: No intervention will take place for this retrospective and observational study.
Study: NCT03317548

Intervention type: DIAGNOSTIC_TEST
Intervention: progesterone
Description: according progesterone level to decide fresh or frozen embryo transfer

Intervention type: DIAGNOSTIC_TEST
Intervention: day 3 embryo
Description: according day 3 embryo to decide fresh or frozen embryo transfer

Intervention type: DIAGNOSTIC_TEST
Intervention: day 3 embryo
Description: according day 3 embryo to decide fresh or frozen embryo transfer
Study: NCT02983110

Intervention type: PROCEDURE
Intervention: Anoscopy with Rectal Tissue Sampling
Description: All subjects will provide 10 pieces of rectal tissue

Intervention type: PROCEDURE
Intervention: Anoscopy with Rectal Tissue Sampling
Description: All subjects will provide 10 pieces of rectal tissue

Intervention type: PROCEDURE
Intervention: Anoscopy with Rectal Tissue Sampling
Description: All subjects will provide 10 pieces of rectal tissue
Study: NCT02983110

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: • Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: • Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: • Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.

Intervention type: PROCEDURE
Intervention: Female Genital Tract Sampling
Description: Cohorts B only will have cervical cells, cervical tissue, and vaginal tissue collected
Study: NCT00909402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
Study: NCT02853162

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ARREST-study
Description: Radiotherapy will be delivered in five fractions of 7 Gy every other day. An additional contrast enhanced MRI scan will be performed after the 2nd treatment fraction, and after 6 and 12 months
Study: NCT03318471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSo4
Description: 50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: 100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes
Study: NCT03291925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective invasive angiography based on CT/CCTA imaging.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure/Surgery: Invasive angiography
Study: NCT06121193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT tool
Description: PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Control
Description: Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool